CA2485733A1 - Vaccines - Google Patents

Vaccines Download PDF

Info

Publication number
CA2485733A1
CA2485733A1 CA002485733A CA2485733A CA2485733A1 CA 2485733 A1 CA2485733 A1 CA 2485733A1 CA 002485733 A CA002485733 A CA 002485733A CA 2485733 A CA2485733 A CA 2485733A CA 2485733 A1 CA2485733 A1 CA 2485733A1
Authority
CA
Canada
Prior art keywords
muc
nucleic acid
vntr
protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002485733A
Other languages
English (en)
French (fr)
Inventor
Neil Burden
Paul Hamblin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2485733A1 publication Critical patent/CA2485733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002485733A 2002-05-24 2003-05-23 Vaccines Abandoned CA2485733A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0212036.8 2002-05-24
GBGB0212036.8A GB0212036D0 (en) 2002-05-24 2002-05-24 Vaccines
PCT/EP2003/005595 WO2003099193A2 (en) 2002-05-24 2003-05-23 Vaccines

Publications (1)

Publication Number Publication Date
CA2485733A1 true CA2485733A1 (en) 2003-12-04

Family

ID=9937387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002485733A Abandoned CA2485733A1 (en) 2002-05-24 2003-05-23 Vaccines

Country Status (7)

Country Link
US (1) US20060062798A1 (https=)
EP (1) EP1507861A2 (https=)
JP (1) JP2005526511A (https=)
AU (1) AU2003237701A1 (https=)
CA (1) CA2485733A1 (https=)
GB (1) GB0212036D0 (https=)
WO (1) WO2003099193A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
CA2595778A1 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
US9140692B1 (en) * 2010-01-08 2015-09-22 Glycozym, Inc. Methods of identifying glycopeptides recognized by disease-associated auto-antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
JP2005526511A (ja) 2005-09-08
WO2003099193A3 (en) 2004-02-19
WO2003099193A2 (en) 2003-12-04
US20060062798A1 (en) 2006-03-23
AU2003237701A1 (en) 2003-12-12
GB0212036D0 (en) 2002-07-03
AU2003237701A8 (en) 2003-12-12
EP1507861A2 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
AU784605B2 (en) Chimeric immunogenic compositions and nucleic acids encoding them
JP3195958B2 (ja) 悪性腫瘍の治療又は予防のための医薬組成物
JP5416968B2 (ja) 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
US20070184023A1 (en) Method for down-regulation of vegf
AU2003240729B2 (en) MUC-1 antigen with reduced number of VNTR repeat units
WO2019101062A9 (zh) 重组疫苗及其应用
US20050063952A1 (en) Immunogenic CEA
JP2008528004A (ja) 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
US20060062798A1 (en) Vaccines
CZ20011521A3 (cs) Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek
US20060147458A1 (en) Vaccines
US20070042047A1 (en) Vaccines
US20040191761A1 (en) Modified adenoviral E1A constructs and methods of use thereof
WO2021170111A1 (zh) 肿瘤免疫增强剂及其制法和应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued